A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Completed · Phase 4

Conditions studied: Type 2 Diabetes, Diabetes Mellitus, Type 2

In brief

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).

Key facts

Study ID

NCT05706506

Run by

Eli Lilly and Company

People needed

152

Starts

2023-03-08

Expected to finish

2023-10-31

Last updated by the study team

2024-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have Type 2 diabetes (T2D)
• Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)
• Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening
• Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months
• No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.

You may not qualify if…

• Have Type 1 Diabetes (T1D)
• Have a clinical history of
• proliferative diabetic retinopathy
• diabetic maculopathy, or
• non-proliferative diabetic retinopathy that requires acute treatment
• Are at high risk for cardiovascular disease or have a history of
• myocardial infarction
• percutaneous coronary revascularization procedure
• carotid stenting or surgical revascularization
• nontraumatic amputation
• peripheral vascular procedure
• cerebrovascular accident
• or hospitalization for congestive heart failure
• Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure
• Have a history of ketoacidosis or hyperosmolar state or coma
• Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.

Where it is running

• Fiel Family and Sports Medicine PC — Tempe, Arizona, United States
• New Hope Research Development — Corona, California, United States
• Velocity Clinical Research, Gardena — Gardena, California, United States
• Velocity Clinical Research, Huntington Park — Huntington Park, California, United States
• Velocity Clinical Research, Huntington Park — Los Angeles, California, United States
• Valley Clinical Trials, Inc. — Northridge, California, United States
• Dream Team Clinical Research — Pomona, California, United States
• Scripps Whittier Diabetes Institute — San Diego, California, United States
• Metabolic Institute of America — Tarzana, California, United States
• CMR of Greater New Haven, LLC — Waterbury, Connecticut, United States
• Velocity Clinical Research, Hallandale Beach — Hallandale, Florida, United States
• East Coast Institute for Research, LLC — Jacksonville, Florida, United States
• Florida Institute For Clinical Research, LLC — Orlando, Florida, United States
• New Tampa Health — Tampa, Florida, United States
• Georgia Clinical Research — Lawrenceville, Georgia, United States
• Endocrine Research Solutions, Inc. — Roswell, Georgia, United States
• Velocity Clinical Research, Valparaiso — Valparaiso, Indiana, United States
• Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa, United States
• Cotton O'Neil Clinic — Topeka, Kansas, United States
• Versailles Family Medicine — Versailles, Kentucky, United States
• Endocrine and Metabolic Consultants — Rockville, Maryland, United States
• Clinical Research Professionals — Chesterfield, Missouri, United States
• Clinical Research of South Nevada — Las Vegas, Nevada, United States
• Palm Research Center Tenaya — Las Vegas, Nevada, United States
• Advanced Medical Research — Maumee, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.